Program
Bosentan
Also written as “bosentan”, “Bosentan 125 mg” and “Bosentan 62.5 mg”.
Its studies are mostly in Pulmonary Arterial Hypertension · Hypertension, Pulmonary · Idiopathic Pulmonary Fibrosis · digital ulcers · Scleroderma, Systemic, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 260 open or running | phase 4since Apr 30, 2004 | Oct 6, 2003 | none ahead |
| Geropharm | 10 open or running | phase 1since Sep 23, 2019 | Sep 23, 2019 | none ahead |
| Hanmi Pharmaceutical | 10 open or running | phase 1since May 20, 2013 | May 20, 2013 | none ahead |
| Humanis Saglık Anonim Sirketi | 10 open or running | phase 1since Jun 26, 2024 | Jun 26, 2024 | none ahead |
| Retinset SL | 10 open or running | phase 1since Aug 22, 2019 | Aug 22, 2019 | none ahead |
Also a collaborator on its studies: Dong-A ST.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 16 studies since Oct 6, 2003.
- Aug 21, 2006Phase 4 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT00367770 · 37 enrolled · United States, Australia, Austria and more
- Oct 20, 2006Phase 3 study in Idiopathic Pulmonary FibrosisJohnson & Johnson · NCT00391443 · 616 enrolled
- Feb 7, 2007Phase 4 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT00433329 · 100 enrolled
- Jan 7, 2008Phase 4 study in Hypertension, PulmonaryJohnson & Johnson · NCT00595049 · 11 enrolled · Australia
- Feb 12, 2008Phase 3 study in Idiopathic Pulmonary FibrosisJohnson & Johnson · NCT00631475 · 128 enrolled
- Oct 14, 2009Phase 2 study in MelanomaJohnson & Johnson · NCT01009177 · 80 enrolled · Australia
- Oct 12, 2010Phase 3 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT01223352 · 64 enrolled
- Apr 15, 2011Phase 3 study in Pulmonary Arterial HypertensionJohnson & Johnson · NCT01338415 · 58 enrolled · United States, Australia, Belarus and more
- Jun 30, 2011Phase 3 study in Persistent Fetal Circulation SyndromeJohnson & Johnson · NCT01389856 · 23 enrolled
- Jul 6, 2011Phase 4 study in Scleroderma, SystemicJohnson & Johnson · NCT01395732 · 18 enrolled · Netherlands
- May 20, 2013Hanmi Pharmaceutical's first study: phase 1 study in Pulmonary Arterial HypertensionNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT01864863 · 28 enrolled · Korea, Republic of
- Aug 22, 2019Retinset SL's first study: phase 1 study in Diabetes MellitusNew to Retinset SLRetinset SL · NCT04068272 · 22 enrolled · Spain
- Sep 23, 2019Geropharm's first study: phase 1 study in FastingNew to GeropharmGeropharm · NCT04101370 · 64 enrolled · Russian Federation
- Jun 26, 2024Humanis Saglık Anonim Sirketi's first study: phase 1 study in Pulmonary Arterial HypertensionNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06484673 · 32 enrolled · Jordan
TargetBeta
“Endothelin receptor, ET-A/ET-B antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| aprocitentanrule | Idorsia Pharmaceuticals | phase 3 | 14 |
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06484673Pulmonary Arterial Hypertension · Jordan | 1 | Completed | Humanis Saglık Anonim Sirketi | May 22, 2024 | 32 |
| NCT04101370Fasting · Russian Federation | 1 | Completed | Geropharm | Jun 20, 2018 | 64 |
| NCT04068272Diabetes Mellitus · Spain | 1 | Completed | Retinset SL | May 20, 2022 | 22 |
| NCT01864863Pulmonary Arterial Hypertension · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | May 2013 | 28 |
| NCT01395732Scleroderma, Systemic · Netherlands | 4 | Completed | Johnson & Johnson | Nov 30, 2012 | 18 |
| NCT01389856Persistent Fetal Circulation Syndrome | 3 | Terminated | Johnson & Johnson | Dec 2013 | 23 |
| NCT01338415Pulmonary Arterial Hypertension · United States, Australia, Belarus and more | 3 | Completed | Johnson & Johnson | Aug 13, 2014 | 58 |
| NCT01223352Pulmonary Arterial Hypertension | 3 | Completed | Johnson & Johnson | Apr 3, 2013 | 64 |
| NCT01009177Melanoma · Australia | 2 | Completed | Johnson & Johnson | Feb 29, 2008 | 80 |
| NCT00631475Idiopathic Pulmonary Fibrosis | 3 | Completed | Johnson & Johnson | Apr 2010 | 128 |
| NCT00595049Hypertension, Pulmonary · Australia | 4 | Completed | Johnson & Johnson | Dec 31, 2008 | 11 |
| NCT00433329Pulmonary Arterial Hypertension | 4 | Completed | Johnson & Johnson | May 2010 | 100 |
| NCT00391443Idiopathic Pulmonary Fibrosis | 3 | Completed | Johnson & Johnson | Feb 2010 | 616 |
| NCT00367770Pulmonary Arterial Hypertension · United States, Australia, Austria and more | 4 | Completed | Johnson & Johnson | Dec 2005 | 37 |
| NCT00360087Hypertension, Pulmonary | 3 | Terminated | Johnson & Johnson | Aug 2007 | 236 |
| NCT00319696digital ulcers | 3 | Completed | Johnson & Johnson | Jan 22, 2009 | 116 |
| NCT00319267Pulmonary Arterial Hypertension | 3 | Completed | Johnson & Johnson | Dec 2006 | 36 |
| NCT00319111Hypertension, Pulmonary | 3 | Completed | Johnson & Johnson | Feb 2009 | 151 |
| NCT00319033Lung Diseases, Interstitial | 3 | Completed | Johnson & Johnson | Feb 2006 | 132 |
| NCT00319020Pulmonary Arterial Hypertension | 3 | Completed | Johnson & Johnson | Oct 28, 2011 | 33 |
| NCT00317486Pulmonary Arterial Hypertension | 4 | Completed | Johnson & Johnson | Apr 2005 | 54 |
| NCT00313222Chronic Thromboembolic Pulmonary Hypertension | 3 | Completed | Johnson & Johnson | Feb 2007 | 157 |
| NCT00313196Hypertension, Pulmonary | 3 | Terminated | Johnson & Johnson | Aug 2007 | 12 |
| NCT00310830Hypertension, Pulmonary | 3 | Terminated | Johnson & Johnson | Aug 2007 | 14 |
| NCT00303459Pulmonary Arterial Hypertension | 4 | Completed | Johnson & Johnson | Dec 2013 | 334 |
| NCT00091715Hypertension, Pulmonary · United States, Australia, Austria and more | 3 | Completed | Johnson & Johnson | Nov 2006 | 185 |
| NCT00082186Hypertension, Pulmonary | 4 | Completed | Johnson & Johnson | Feb 2007 | 22 |
| NCT00077584digital ulcers | 3 | Completed | Johnson & Johnson | Mar 2005 | 188 |
| NCT00071461Idiopathic Pulmonary Fibrosis · United States, Canada, France and more | 3 | Completed | Johnson & Johnson | Sep 2005 | 158 |
| NCT00070590Pulmonary Fibrosis | 3 | Completed | Johnson & Johnson | Sep 2005 | 132 |
How it is read
Names in the registry
- “Bosentan”, 19 entries
- “bosentan”, 12 entries
- “Bosentan 125 mg”, 3 entries
- “Bosentan 62.5 mg”, 2 entries
- “Bosentan Dispersible Tablets”, 1 entry
Conditions, from the studies’ own filings
- Pulmonary Arterial Hypertension, 14 studies
- Hypertension, Pulmonary, 6 studies
- Idiopathic Pulmonary Fibrosis, 3 studies
- digital ulcers, 2 studies
- Scleroderma, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.